ADX-850

Phase 1Small molecule

AADARx Pharmaceuticals, Inc.

ADX-850 is one of 27 small molecule programs targeting Hypertension. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypertensionActive, not recruiting

HypertensionPhase 1

Active, not recruiting

Competition

Competitive Landscape

566 competitors in Hypertension

#DrugCompanyPhaseTrials

Apresoline

Novartis

Preclinical

7 2

Zebeta

Teva

Preclinical

6 3

Edarbi

Takeda

Preclinical

4 4

Aceon

Institut de Recherches Internationales Servier

Preclinical

5 5

Alphagan

Winrevair

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

2 8

Disalcid

JJoslin Diabetes Center

Preclinical

1 9

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Hypertension

NCT06205628

Clinical

Trials by Indication[1]

Hypertension1 trial

Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension

Active, not recruiting·AADARx Pharmaceuticals, Inc.·Phase 1·NCT06205628·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ADX-850. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ADX-850 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ADX-850. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ADARx Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AADARx Pharmaceuticals, Inc.

ADX-850

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Hypertension1 trial

References

Drug Info

Quick Facts

Related News